Who are Turoctocog alfa pegol (N8-GP)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Afstyla®, Moroctocog alfa (AF-CC), Kogenate (BAY 14-2222), Recombinant Human Coagulation FVIII, Efmoroctocog Alfa Injection [Eloctate], OBIZUR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/turoctocog-alfa-pegol-n8-gp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Turoctocog alfa pegol (N8-GP) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Turoctocog alfa pegol (N8-GP) (Turoctocog alfa pegol (N8-GP)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant coagulation factor VIII (pegylated). Area: Hematology.

phase 3 Recombinant coagulation factor VIII (pegylated) Coagulation factor VIII Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Turoctocog alfa pegol (N8-GP) (Turoctocog alfa pegol (N8-GP)) — Novo Nordisk A/S. Turoctocog alfa pegol is a recombinant human coagulation factor VIII with extended half-life achieved through PEGylation, which replaces deficient clotting factor in hemophilia A patients.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Turoctocog alfa pegol (N8-GP) TARGET	Turoctocog alfa pegol (N8-GP)	Novo Nordisk A/S	phase 3	Recombinant coagulation factor VIII (pegylated)	Coagulation factor VIII
Afstyla®	Afstyla®	CSL Behring	marketed	Recombinant clotting factor VIII	Factor VIII (coagulation factor VIII)
Moroctocog alfa (AF-CC)	Moroctocog alfa (AF-CC)	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Kogenate (BAY 14-2222)	Kogenate (BAY 14-2222)	Bayer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Recombinant Human Coagulation FVIII	Recombinant Human Coagulation FVIII	Sinocelltech Ltd.	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII
Efmoroctocog Alfa Injection [Eloctate]	Efmoroctocog Alfa Injection [Eloctate]	The League of Clinical Research, Russia	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII (intrinsic tenase complex)
OBIZUR	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant coagulation factor VIII (pegylated) class)

Novo Nordisk A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Turoctocog alfa pegol (N8-GP) — Competitive Intelligence Brief. https://druglandscape.com/ci/turoctocog-alfa-pegol-n8-gp. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab